India shares higher at close of trade; Nifty 50 up 2.63%
Investing.com – India equities were higher at the close on Tuesday, as gains in the Metals, Oil & Gas and Capital Goods sectors propelled shares higher. At the close in NSE, the Nifty 50...
Strong Buy
or
Sun Pharma News & Analysis
-
-
Black Box Ltd leads gainers in 'A' group
Elgi Equipments Ltd, Varroc Engineering Ltd, Sun Pharma Advanced Research Company Ltd and IRB Infrastructure Developers Ltd are among the other gainers in the BSE's 'A' group today, 16 May...
-
India shares lower at close of trade; Nifty 50 down 0.16%
Investing.com – India equities were lower at the close on Friday, as losses in the Metals, Power and Banking sectors propelled shares lower. At the close in NSE, the Nifty 50 lost 0.16% to...
-
Share Market LIVE: Sensex rises 100 pts, Nifty below 15,850; Sun Pharma, M&M top gainers
Sensex trading 106 points higher at 53,036 and Nifty rises 33 points to 15,831 in the afternoon session.
-
Sun Pharma jumps 4% on receiving USFDA nod for Mesalamine capsule
The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug...
-
Sun Pharma gets USFDA approval for generic Mesalamine capsules
The drug major has received final approval from the US drug regulator for its Abbreviated New Drug Application (ANDA) for generic Mesalamine extended release capsules, 500 mg.
-
Sun Pharma, L&T, Tata Motors, SBI in spotlight
Sun Pharmaceutical Industries: The drug major has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic Mesalamine extended release capsules, 500 mg....
-
Stocks in focus: SBI, Anupam Rasayan, Sun Pharma and more
Nifty futures on the Singapore Exchange traded 166 points, or 1.05 per cent, higher at 15,982.50, signaling that Dalal Street was headed for a positive start on Friday. Here are a few stocks...
-
Sun Pharma gets USFDA nod for generic drug Mesalamine extended release capsules
The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug...
-
Sun Pharma gets 10 observations for Halol plant from USFDA
A Form 483 is issued after completion of inspection of a facility and when the investigator has observed that may be in violation of the regulator’s rules.
-
India shares lower at close of trade; Nifty 50 down 0.38%
Investing.com – India equities were lower at the close on Tuesday, as losses in the Metals, Power and Real Estate sectors propelled shares lower. At the close in NSE, the Nifty 50 lost...
-
Sun Pharma stock slips 4% after USFDA issues observations for Halol plant
Sun Pharma stock slipped 4.41 per cent to Rs 846.35 against the previous close of Rs 885.35 on BSE. The stock has fallen after two days of consecutive gain.
-
Sun Pharma Gets, 10 Observations From USFDA For Halol Plant
Sun Pharma on Tuesday said the US health regulator has issued a 'Form 483' with ten observations after inspecting its Halol-based manufacturing plant in Gujarat. As per USFDA, a Form 483 is...
-
Sun Pharma slips over 2% after USFDA issues observations for Halol facility
In the past five days, the stock has fallen over 5 per cent. In comparison, the S&P BSE Sensex declined 3.75 per cent during the same period
-
Sun Pharma Share Prices Drop After Facility Concludes USFDA Audit with 10 Observations
Sun Pharmaceutical Industries' share price fell over four per cent in morning trade after the company received 10 observations for its Halol plant from the United States Food and Drug...
-
Sun Pharma's Halol plant gets Form 483 with 10 observations from the USFDA
The Sun Pharma's Halol facility was classified as 'Official Action Indicated (OAI)' in March 2020, and was awaiting re-inspection from the US regulator USFDA.
-
Sun Pharma gets 10 observations from USFDA for Halol plant
As per USFDA, a Form 483 is issued to a firm#39;s management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute...
-
Sun Pharma falls after plant gets 10 observations from US
The company is preparing a response to the observations which will be submitted within 15 business days.
-
Sun Pharma's Halol facility concludes USFDA audit with 10 observations
Powered by Capital Market - Live News
-
US FDA issues Form 483 with 10 observations to Sun Pharma’s Halol unit
Listed pharmaceutical entity Sun Pharmaceutical Industries on Tuesday informed the exchanges that the US FDA has issued Form 483 with ten observations to the company’s Halol unit.
-
Day Trading Guide: Sun Pharma among 4 stocks that analysts recommend for Friday
“The Nifty formed inside bar chart pattern (i.e. swung between its prior session’s high/low range), the said pattern indicates indecisiveness. Hence, follow-up action needs to be closely...
-
Foreign Investors Slash & Add Stakes in These Nifty Stocks in Q4; Bearish Sectors
By Malvika Gurung Investing.com -- Foreign investors have continued their selling spree in the quarter ending March 2022, offloading Indian shares worth over Rs 1.1 lakh crore, while selling...
-
Here’s Why: Nifty IT Corrects 18% YTD, 13% in Apr; Infosys Plunges 17%, TCS & More
By Malvika Gurung Investing.com -- The highly-attractive IT stocks in global markets and the domestic have witnessed sharp sell-offs recently, majorly led by concerns compounding on the...
-
India shares lower at close of trade; Nifty 50 down 0.83%
Investing.com – India equities were lower at the close on Friday, as losses in the Oil & Gas, Public Sector Undertakings and Power sectors propelled shares lower. At the close in NSE, the...
-
Equities up marginally during early trade
New Delhi, April 28 (IANS) Indian equity benchmarks rose marginally during early trade on Thursday.At 9.17 a.m., Sensex was at 57,096 points, up 0.5 per cent or 277 points, whereas Nifty at...
-
3 Indian pharma cos recall products in US market
Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons, as per the latest enforcement report by the US Food and...
-
Aurobindo, Sun Pharma, Jubilant recall products in US market: USFDA
Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons
-
4 Companies That Stand To Win Big As Interest Rates Rise
Interest rates are rising again. This is driving investors to put their money into sectors with limited impact from market volatility.
-
India shares lower at close of trade; Nifty 50 down 0.31%
Investing.com – India equities were lower at the close on Wednesday, as losses in the Auto, Banking and Real Estate sectors propelled shares lower. At the close in NSE, the Nifty 50...
-
52-week highs, 52-week lows: Adani Enterprises, Sun Pharma among 152 stocks to hit new highs on BSE
Adani Ports, Eicher Motors, Tata Motors, ONGC, Tata Consumer Products were the top gainers in Nifty pack, and HDFC Bank, Bajaj Finserv, HDFC, Reliance, Hindalco were the laggards.
-
India shares higher at close of trade; Nifty 50 up 1.18%
Investing.com – India equities were higher at the close on Friday, as gains in the Public Sector Undertakings, Power and Oil & Gas sectors propelled shares higher. At the close in NSE, the...
-
Equity indices settle lower in volatile trade; Sensex down 304 pts (Ld)
New Delhi, March 23 (IANS) Paring the entire opening session gains, India's key equity indices -- Sensex and Nifty -- settled on a negative note on Wednesday.Sensex settled 0.5 per cent or...
-
India shares lower at close of trade; Nifty 50 down 0.98%
Investing.com – India equities were lower at the close on Monday, as losses in the Power, Fast Moving Consumer Goods and Banking sectors propelled shares lower. At the close in NSE, the...
-
India shares higher at close of trade; Nifty 50 up 1.87%
Investing.com – India equities were higher at the close on Wednesday, as gains in the Real Estate, Metals and Oil & Gas sectors propelled shares higher. At the close in NSE, the Nifty 50...
-
Equity indices in green; Sensex, Nifty up over 1% each
New Delhi, March 16 (IANS) India's key equity indices -- Sensex and Nifty -- traded in the green in the opening session on Wednesday. At 9.54 a.m., Sensex was 1.4 per cent or 777 points up...
-
Equity Indices a Tad Down in Early Trade
New Delhi, March 15 (IANS) India's key equity indices -- Sensex and Nifty -- traded marginally lower in early session on Tuesday. At 9.36 a.m., Sensex was 0.1 percent or 38 points down at...
-
India shares higher at close of trade; Nifty 50 up 1.45%
Investing.com – India equities were higher at the close on Monday, as gains in the Banking, IT and Technology sectors propelled shares higher. At the close in NSE, the Nifty 50 rose 1.45%,...
-
Indices close week with minor gains, Cipla top mover (Ld)
New Delhi, March 11 (IANS) Rally in Indian benchmark equity indices continued for fourth consecutive sessions as it settled marginally higher on Friday. "Indices remained range bound today...
-
India shares higher at close of trade; Nifty 50 up 0.21%
Investing.com – India equities were higher at the close on Friday, as gains in the Healthcare, Public Sector Undertakings and Oil & Gas sectors propelled shares higher. At the close in NSE,...
-
Equity indices extend gains; Sensex up nearly 300 pts
New Delhi, March 11 (IANS) India's benchmark equity indices extended their gains from the previous session and increased in the opening session on Friday. With Friday's rally, indices have...
-
Equity indices up in early trade; Sensex rises 250 pts
New Delhi, March 9 (IANS) India's key indices -- S&P BSE Sensex and NSE Nifty50 -- extended their gains from the previous day's closing and rallied in early trade on Wednesday. At 9.55 a.m.,...
-
Stocks in Focus on Mar 9: Sun Pharma, TCS, NMDC & More
By Malvika Gurung Investing.com -- Sun Pharmaceuticals (NS:SUN): The drugmaker subsidiary Taro Pharmaceuticals USA has acquired the subsidiary companies of the Swiss pharma company Galderma,...
-
Market Close: Sensex Ends Higher After 4 Sessions, Nifty Metal Slumps & More
By Malvika Gurung Investing.com -- Indian equity benchmark indices ended a choppy session higher, putting an end to a four-session losing run on Tuesday, led by a strong recovery in...
-
India shares higher at close of trade; Nifty 50 up 0.95%
Investing.com – India equities were higher at the close on Tuesday, as gains in the Real Estate, IT and Technology sectors propelled shares higher. At the close in NSE, the Nifty 50 gained...
-
India shares lower at close of trade; Nifty 50 unchanged
Investing.com – India equities were lower at the close on Thursday, as in the sectors propelled shares . At the close in NSE, the Nifty 50 unchanged 0% to hit a new 6-month low, while the...
-
Stocks in Focus on Feb 24: RIL, Vedanta, Dabur & More
By Malvika Gurung Investing.com -- Reliance Industries: Wealth management company Bernstein has initiated an ‘Outperform’ rating on the oil-to-telecom conglomerate, projecting its retail...
-
Market on Monday: Nifty, Sensex End Choppy Day in Red, Extends Losses to 4th Day
By Malvika Gurung Investing.com -- Indian equity benchmark indices ended a volatile session lower on Monday, extending losses to the fourth straight day, amid continued tensions between...
-
India shares lower at close of trade; Nifty 50 down 0.40%
Investing.com – India equities were lower at the close on Monday, as losses in the Oil & Gas, Metals and Power sectors propelled shares lower. At the close in NSE, the Nifty 50 fell 0.40%,...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
